JPRN-UMIN000017744
Completed
未知
Allogeneic hematopoietic stem cell transplantation for elderly patients - Allo-HSCT for elderly patients
nivesity of Tokyo Hospital, Department of Hematology and Oncology0 sites50 target enrollmentMay 30, 2015
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- nivesity of Tokyo Hospital, Department of Hematology and Oncology
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\) Presence of other lethal complications. (2\) Severe heart disease (ejection fraction \< 40 %, uncontrollable arrhythmia or hypertension). (3\) Severe kidney dysfunction (CCr \< 30 ml/min). (4\) Severe respiratory diease (PaO2 \< 70 mmHg, DLCO \< 50% or FEV1\.0 \< 60 %). (5\) Severe liver dysfunction (T.Bil \> 2\.5 mg/dl, cirrhosis). (6\) Cases considered to be not suitable in the conference of our department.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-haploidentical related donor using reduced dose of posttransplantation high-dose cyclophosphamide (PTCy) for poor prognosis or refractory hematological malignancies (OCU16-2)Acute myeloid leukemia(AML) Acute lymphoblastic leukemia(ALL) Acute leukemias of ambiguous lineage Myelodysplastic syndrome(MDS) Chronic myeloid leukemia(CML) Adult T-cell leukemia/lymphoma(ATLL) Malignant lymphoma(ML)JPRN-UMIN000026028Osaka City University33
Recruiting
Phase 2
Allogeneic hematopoietic stem cell transplantation from HLA6/8-4/8 matched related donor for poor prognostic or refractory hematologic malignancy and solid tumor - Ibaraki Children's Hospital phase II studyAcute leukemia, malignant lymphoma, and solid tumorJPRN-UMIN000027010Ibaraki Children's Hospital30
Completed
Phase 2
Allogeneic hematopoietic stem cell transplantation for aplastic anemia using low-dose anti-thymocyte globuliJPRN-UMIN000006071Kanto Study Group for Cell Therapy28
Active, not recruiting
Phase 1
Stem cells transplant from matched donor in patients with chronic myeloid leukemia who do not improve with TKI therapyChronic Myeloid LeukemiaMedDRA version: 18.0Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-003126-40-ITIVERSITà DEGLI STUDI MILANO BICOCCA20
Completed
Not Applicable
Allogeneic hematopoietic stem cell transpalntation using Thymoglobulin for patients with T-cell malignancyT-cell malignancyJPRN-UMIN000015736ational Cancer Center Hospital15